Salix Expects Acquisition Of Oceana, Two Products, To Be Quickly Accretive
This article was originally published in The Pink Sheet Daily
Executive Summary
Although privately held Oceana’s two products – Solesta and Deflux – are regulated by FDA as Class III medical devices, Salix intends to market them with existing sales forces.
You may also be interested in...
Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011
Medical device companies raised $800 million in the fourth quarter of 2011, and venture capital represented half of that amount. Just over $4 billion was spent to acquire medical device companies, down 50% from Q3’s $8 billion. In vitro diagnostics/research financings were well above the previous quarter, raking in a total of $269 million, with late-stage rounds again bringing in most of the Q4 money. Only five M&A deals were completed, totalling $915 million – way down from Q3’s $2.8 billion for the same number of deals.
Start-Up Quarterly Statistics, Q4 2011
Biopharma start-ups raised $693 million in Q4 2011, up 131% from Q3. Device companies brought in $111 million, and diagnostics firms raised $120 million total, $96 million of which was from Biocartis’ Series C. Cancer was the most prevalent therapeutic area for biopharma alliances. And in great contrast to Q3’s one M&A deal involving a start-up company, Q4 saw nine start-up acquisitions.
Amitiza Hits Mark In Confirmatory Opioid-Induced Bowel Dysfunction Study
Sucampo/Takeda’s constipation treatment Amitiza meets primary endpoint in Phase III study of OBD, with a clean safety profile. Sucampo now sets its sights on a supplemental NDA for a third indication.